Related Experiment Videos
[Adjuvant therapy in lymph node positive prostate carcinoma?]
1Urologische Klinik, Klinikum Grosshadern, Ludwig-Maximilians-Universität, München.
Der Urologe. Ausg. A
|May 1, 1998
Summary
Curing lymphnode-positive prostate cancer is challenging with current treatments. Adjuvant endocrine therapy may prolong disease-free survival, but optimal treatment strategies require further research and individualized patient care.
Area of Science:
- Oncology
- Urology
Context:
- Prostate cancer with lymphnode metastasis presents a significant clinical challenge.
- Current curative treatments like radiotherapy, surgery, and androgen deprivation have limited success rates.
- Serum PSA levels rise inevitably, followed by clinical recurrence within 5-10 years.
Purpose:
- To review the current evidence and clinical approaches for managing lymphnode-positive prostate cancer.
- To highlight the lack of prospective trials and definitive scientific proof for optimal adjuvant treatment.
- To emphasize the reliance on clinical experience and literature interpretation for treatment decisions.
Summary:
- Few patients with lymphnode-positive prostate cancer achieve a cure with standard therapies.
- Adjuvant endocrine treatment, based on retrospective data, shows potential for prolonged disease-free survival.
- Treatment decisions are currently guided by physician experience and available literature due to a lack of high-level evidence.
Impact:
- Informs clinical decision-making for prostate cancer patients with lymphnode metastasis.
- Underscores the need for prospective research into effective adjuvant therapies.
- Promotes a personalized approach to managing advanced prostate cancer.